Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Apr 08, 2026

Coca-Cola (KO): Consolidating in a Long-Term Rising Channel

Key Takeaways

  • KO maintains a long-term rising channel spanning 18 years, with recent price action showing a pullback from the upper boundary near the 52-week high of $82.00.
  • Current price around $76 trades above key moving averages like the 50-day SMA at $76.14 and 200-day at $77.34 (mixed signals), confirming overall bullish structure.
  • RSI(14) at 67 indicates buy momentum but nearing overbought, while MACD at 0.32 signals buy.
  • Support levels at $75, $72, and deeper at $66.50 (near 1W MA200); resistance at $77.34-$78 and $82.
  • Volume below 65-day average of 18M shares suggests cautious trading amid consolidation.

Understanding the Long-Term Trend

The chart of Coca-Cola Company (KO) reveals a persistent long-term uptrend within an 18-year rising channel established since the 2008 financial crisis. Price has formed higher highs and higher lows, underscoring bullish control. Recently, after touching near the channel's upper trendline and the 52-week high of $82.00, KO has entered a pullback phase over the last 30 days, declining about 1-2% monthly while remaining above major trend support. From what I see, this structure points to consolidation rather than reversal, with traders eyeing continuation if support holds.

Critical Support and Resistance Zones

Key support clusters around $75 (recent hold level), $72 (prior consolidation low), and $66.50 (confluence of lower channel bound, 1W MA200, and historical correction target). A breach below $66.50 could accelerate downside toward $65.35 (52-week low). Resistance begins at the pivot R1 of $77.34, extending to $78 (prior highs) and the channel top near $82.00. Pivot points (classic) show S1 at $77.01 and R2 at $77.46, framing near-term range-bound action. One thing that stands out is how these levels align with historical price behavior.

Moving Averages in Focus

KO price sits above short-term moving averages, including the MA5 at $77.15 (buy), MA10 at $76.99 (buy), MA20 at $76.65 (buy), and MA50 at $76.14 (buy). The MA100 at $76.00 supports buy signals, though the MA200 SMA at $77.34 flashes a sell as price trades just below it. Exponential MAs align bullish, with price above the 50-day EMA at $76.35. This golden cross configuration (50-day above 200-day in recent periods) reinforces the intermediate uptrend. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Momentum Indicators Breakdown

RSI(14) reading of 67 signals buy territory, approaching overbought alongside STOCH at 87.5 (overbought) and Williams %R at -3.06. MACD(12,26) at 0.32 with positive histogram indicates building bullish momentum. ADX(14) at 30 confirms a strong trend, while CCI(14) at 141 supports buy. Oscillators suggest caution for short-term pullbacks but no divergence warning trend exhaustion. In my view, this is important because it shows sustained momentum without immediate reversal risks.

Volume Patterns and Market Activity

Recent sessions show volume at 12-14M shares, below the 65-day average of 18M, reflecting reduced conviction during the pullback. No major spikes noted, but steady participation on up days supports accumulation near supports. Lower volume on declines aligns with bullish price action over the quarter. I’m watching this closely, as a volume pickup could confirm the next move.

Why I Use Tickeron’s AI Daily Buy/Sell Signals

In my own analysis workflow, I rely on Tickeron’s AI Daily Buy/Sell Signals to leverage artificial intelligence in scrutinizing vast datasets, including technical indicators, price patterns, and historical behaviors for KO. These signals identify potential buy or sell opportunities by detecting trend shifts, momentum divergences, and pattern completions like channel pullbacks. I use them to pinpoint entries/exits, validate breakouts above $77 or supports at $75, and refine strategies amid consolidation. Neutral to buy overall, they complement manual chart review for informed decisions—explore the tool for real-time KO insights.

Technical Outlook and Levels to Monitor

Traders monitor a hold above $75 for bullish resumption toward $78-$82 channel resistance, with volume pickup signaling strength. Failure at $72 eyes $66.50 demand zone. Watch RSI for overbought relief, MACD crossovers, and MA200 reclaim. Breakout above R1 $77.34 targets prior highs; deeper correction tests long-term channel integrity. This setup keeps me focused on the bigger picture.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: KO

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


KO in upward trend: price may jump up because it broke its lower Bollinger Band on September 30, 2026

KO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 18 of 40 cases where KO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 45%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where KO advanced for three days, in 148 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 44%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KO as a result. In 31 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 40%.

The Moving Average Convergence Divergence Histogram (MACD) for KO turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 17 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 35%.

KO moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KO crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 40%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 29%.

The Aroon Indicator for KO entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.

The Tickeron SMR rating for this company is 24 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. KO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.373) is normal, around the industry mean (6.793). P/E Ratio (26.180) is within average values for comparable stocks, (43.051). Projected Growth (PEG Ratio) (3.960) is also within normal values, averaging (3.732). Dividend Yield (0.024) settles around the average of (0.014) among similar stocks. KO's P/S Ratio (7.559) is slightly higher than the industry average of (2.785).

Notable companies

The most notable companies in this group are Coca-Cola Company (NYSE:KO), PepsiCo (NASDAQ:PEP).

Industry description

Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.

Market Cap

The average market capitalization across the Beverages: Non-Alcoholic Industry is 45.7B. The market cap for tickers in the group ranges from 1.51K to 375.1B. KO holds the highest valuation in this group at 375.1B. The lowest valued company is NTEI at 1.51K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Non-Alcoholic Industry was -1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -13%. REED experienced the highest price growth at 7%, while BNKK experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Beverages: Non-Alcoholic Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 60
Price Growth Rating: 60
SMR Rating: 64
Profit Risk Rating: 76
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
KO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of non-alcoholic beverages

Industry BeveragesNonAlcoholic

Industry
Beverages Non Alcoholic
Address
One Coca-Cola Plaza
Phone
+1 404 676-2121
Employees
65900
Web
https://www.coca-colacompany.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.